Concepedia

Author

Dorota Borys

GlaxoSmithKline (Belgium)ORCID

Also Known As

Borys, D., Borys, Dorota, D Borys, D. Borys, Dorota Borys, Javier Ruiz-Guiñazú

92

Publications

2.6K

Citations

26

H-Index

14

Concepts

All Affiliations

GlaxoSmithKline (Belgium)Finnish Institute for Health and WelfareGlaxosmithkline (Finland)London School of Hygiene & Tropical MedicineGlaxoSmithKline (United Kingdom)
DB

About

Dorota Borys is an author at GlaxoSmithKline (Belgium) specializing in vaccination, medicine, and infection control.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

760

2

Immunology

2

2

295

3

Allergy

1

1

373

4

Microbiology

1

1

71

5

Antibiotics

1

1

92

Dorota Borys

×

42

Publications

2.3K

Citations

24

H-Index

YearCitations

Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials

Roman Prymula, Claire‐Anne Siegrist, Roman Chlíbek,

The Lancet

2009

373

Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial

Arto A. Palmu, Jukka Jokinen, Dorota Borys,

The Lancet

2012

224

Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial

Miguel Tregnaghi, Xavier Sáez‐Llorens, Pío López,

PLoS Medicine

2014

221

Effects of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugate Vaccine on Nasopharyngeal Bacterial Colonization in Young Children: A Randomized Controlled Trial

Menno R. van den Bergh, Judith Spijkerman, Kristien Swinnen,

Clinical Infectious Diseases

2012

133

Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3–4 trial

Arto A. Palmu, Jukka Jokinen, Heta Nieminen,

The Lancet Infectious Diseases

2013

92

Effectiveness of the 10-Valent Pneumococcal Nontypeable<i>Haemophilus influenzae</i>Protein D–Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media—A Double-Blind Randomized Clinical Trial in Finland

Timo Vesikari, Aino Forstén, Ilkka Seppä,

Journal of the Pediatric Infectious Diseases Society

2016

81

Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study

Aderonke Odutola, Martin O. C. Ota, Martín Antonio,

Vaccine

2017

80

Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage

Roman Prymula, I Hanovcová, Miroslav Špliňo,

Vaccine

2011

71

Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study

Geert Leroux‐Roels, Cathy Maes, Fien De Boever,

Vaccine

2014

68

Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial

Roman Prymula, Petr Pazdiora, Magali Traskine,

Vaccine

2014

64

Page 1